Sciety

TIRmed Pharma AB is a pharmaceutical company based in Bromma, Sweden, established in 2018. The company focuses on developing topical treatments for eczema, specifically targeting mild to moderate symptoms of atopic dermatitis. Its primary product is a non-steroidal cream designed to reduce inflammation and alleviate itching associated with the condition. TIRmed Pharma aims to address significant clinical needs within the dermatological space through its innovative drug candidates.

PeptiSystems is a company that specializes in the manufacturing and supply of instruments for solid-phase synthesis, specifically targeting peptide and oligonucleotide therapeutics. Their innovative medical instruments facilitate the production of peptides, which are essential for developing bioactive molecules used in various pharmaceuticals. This capability supports healthcare professionals in treating a range of diseases, including AIDS, HIV, and diabetes. By providing advanced solutions for peptide synthesis, PeptiSystems plays a vital role in the biotechnology sector, contributing to the development of important therapeutics.

TIRmed Pharma AB is a pharmaceutical company based in Bromma, Sweden, established in 2018. The company focuses on developing topical treatments for eczema, specifically targeting mild to moderate symptoms of atopic dermatitis. Its primary product is a non-steroidal cream designed to reduce inflammation and alleviate itching associated with the condition. TIRmed Pharma aims to address significant clinical needs within the dermatological space through its innovative drug candidates.

Capitainer AB, established in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacture of innovative blood collection devices. Their flagship product enables patients to safely and accurately collect predefined volumes of dried blood spots at home, reducing the need for travel and healthcare resources traditionally spent on blood sampling. This technology offers significant cost savings and environmental benefits for healthcare providers managing large numbers of conventional blood samples annually.

PharmNovo AB, established in 2008 and headquartered in Lund, Sweden, specializes in developing novel therapeutic drugs for neuro diseases, with a focus on reducing chronic pain through neuroscience and translational medicine. The company's primary product, PN6047, is designed to alleviate chronic pain and combat hypersensitivity disorders by targeting Delta Opioid Receptors (DORAs), distinct from traditional opioids that often lead to addiction and toxicity. PharmNovo aims to address the significant unmet medical need for safe and effective chronic pain treatments, affecting approximately 30% of adults in the United States and Europe.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Encare AB, established in 2009 and headquartered in Stockholm, Sweden, specializes in web-based software solutions designed to enhance post-surgical care. The company's primary product is an interactive platform supporting surgical clinics worldwide in implementing and maintaining Enhanced Recovery After Surgery (ERAS) protocols. This platform facilitates data collection, documentation, and follow-up on critical performance parameters, providing real-time feedback to improve efficiency and quality of care while generating substantial healthcare savings. Encare has rights to commercialize ERAS Society's surgical protocols and has rolled out its audit system to over 120 hospitals across 13 countries.

Capitainer AB, established in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacture of innovative blood collection devices. Their flagship product enables patients to safely and accurately collect predefined volumes of dried blood spots at home, reducing the need for travel and healthcare resources traditionally spent on blood sampling. This technology offers significant cost savings and environmental benefits for healthcare providers managing large numbers of conventional blood samples annually.

Akiram Therapeutics is a Swedish biotech company based in Uppsala, specializing in the development of targeted radioimmunotherapy for cancer. The company's innovative approach utilizes a proprietary antibody that targets the cancer marker CD44v6, combined with a radiation component. This therapy has shown promising preclinical results in cancer models for conditions that currently lack effective treatments. Akiram's drug candidate is positioned to be classified as an orphan drug and has the potential to be recognized as first-in-class. The company is advancing research in various cancer indications, including head and neck cancer, acute myeloid leukemia, lung cancer, and aggressive thyroid cancer. With a team of experts in radiation science research, cancer precision medicine, and drug development, Akiram Therapeutics is dedicated to creating novel radioactive cancer-targeting molecules and pharmaceuticals aimed at improving diagnostics and therapeutic outcomes for patients with solid tumors.

PharmNovo AB, established in 2008 and headquartered in Lund, Sweden, specializes in developing novel therapeutic drugs for neuro diseases, with a focus on reducing chronic pain through neuroscience and translational medicine. The company's primary product, PN6047, is designed to alleviate chronic pain and combat hypersensitivity disorders by targeting Delta Opioid Receptors (DORAs), distinct from traditional opioids that often lead to addiction and toxicity. PharmNovo aims to address the significant unmet medical need for safe and effective chronic pain treatments, affecting approximately 30% of adults in the United States and Europe.

PharmNovo AB, established in 2008 and headquartered in Lund, Sweden, specializes in developing novel therapeutic drugs for neuro diseases, with a focus on reducing chronic pain through neuroscience and translational medicine. The company's primary product, PN6047, is designed to alleviate chronic pain and combat hypersensitivity disorders by targeting Delta Opioid Receptors (DORAs), distinct from traditional opioids that often lead to addiction and toxicity. PharmNovo aims to address the significant unmet medical need for safe and effective chronic pain treatments, affecting approximately 30% of adults in the United States and Europe.

Encare AB, established in 2009 and headquartered in Stockholm, Sweden, specializes in web-based software solutions designed to enhance post-surgical care. The company's primary product is an interactive platform supporting surgical clinics worldwide in implementing and maintaining Enhanced Recovery After Surgery (ERAS) protocols. This platform facilitates data collection, documentation, and follow-up on critical performance parameters, providing real-time feedback to improve efficiency and quality of care while generating substantial healthcare savings. Encare has rights to commercialize ERAS Society's surgical protocols and has rolled out its audit system to over 120 hospitals across 13 countries.

Capitainer AB, established in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacture of innovative blood collection devices. Their flagship product enables patients to safely and accurately collect predefined volumes of dried blood spots at home, reducing the need for travel and healthcare resources traditionally spent on blood sampling. This technology offers significant cost savings and environmental benefits for healthcare providers managing large numbers of conventional blood samples annually.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Synartro is a Swedish research and development company specializing in the advancement of treatments for osteoarthritis (OA) through innovative drug delivery technology. The company focuses on developing local injection therapies that utilize patented delivery methods to combine existing proven drugs with enhanced efficacy, enabling sustained release without systemic side effects. Its lead program, SYN321, features a novel therapy that covalently binds diclofenac to hyaluronan, targeting knee osteoarthritis—a condition that affects many patients who currently experience inadequate pain relief. Synartro aims to improve the management of OA and has the potential to expand its offerings to include treatments for other related conditions in the future.

SAGA Diagnostics AB is a Swedish company specializing in personalized cancer diagnostics and disease monitoring through molecular genetic analyses, focusing on circulating tumor DNA (ctDNA). Founded in 2016 as a spin-out from a research group at Lund University, SAGA aims to enhance precision cancer medicine and improve patient survival rates with its minimally-invasive liquid biopsy testing services. The company provides a range of services, including gene mutation analysis and treatment monitoring, utilizing advanced technologies such as massively parallel sequencing. SAGA's proprietary tests enable oncologists and biopharmaceutical companies to detect actionable mutations, stratify patient groups, and monitor treatment responses with high sensitivity, thereby contributing significantly to advancements in cancer research and clinical diagnostics.

Capitainer AB, established in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacture of innovative blood collection devices. Their flagship product enables patients to safely and accurately collect predefined volumes of dried blood spots at home, reducing the need for travel and healthcare resources traditionally spent on blood sampling. This technology offers significant cost savings and environmental benefits for healthcare providers managing large numbers of conventional blood samples annually.

Synartro is a Swedish research and development company specializing in the advancement of treatments for osteoarthritis (OA) through innovative drug delivery technology. The company focuses on developing local injection therapies that utilize patented delivery methods to combine existing proven drugs with enhanced efficacy, enabling sustained release without systemic side effects. Its lead program, SYN321, features a novel therapy that covalently binds diclofenac to hyaluronan, targeting knee osteoarthritis—a condition that affects many patients who currently experience inadequate pain relief. Synartro aims to improve the management of OA and has the potential to expand its offerings to include treatments for other related conditions in the future.

PharmNovo AB, established in 2008 and headquartered in Lund, Sweden, specializes in developing novel therapeutic drugs for neuro diseases, with a focus on reducing chronic pain through neuroscience and translational medicine. The company's primary product, PN6047, is designed to alleviate chronic pain and combat hypersensitivity disorders by targeting Delta Opioid Receptors (DORAs), distinct from traditional opioids that often lead to addiction and toxicity. PharmNovo aims to address the significant unmet medical need for safe and effective chronic pain treatments, affecting approximately 30% of adults in the United States and Europe.

Synartro is a Swedish research and development company specializing in the advancement of treatments for osteoarthritis (OA) through innovative drug delivery technology. The company focuses on developing local injection therapies that utilize patented delivery methods to combine existing proven drugs with enhanced efficacy, enabling sustained release without systemic side effects. Its lead program, SYN321, features a novel therapy that covalently binds diclofenac to hyaluronan, targeting knee osteoarthritis—a condition that affects many patients who currently experience inadequate pain relief. Synartro aims to improve the management of OA and has the potential to expand its offerings to include treatments for other related conditions in the future.

Empe Diagnostics specializes in developing rapid diagnostic solutions for infectious diseases, particularly targeting drug-resistant Tuberculosis (TB) and Sexually Transmitted Diseases (STDs). The company focuses on creating simple and efficient diagnostic kits that facilitate combinatorial and confirmatory point-of-care testing. By prioritizing early-stage diagnostics, Empe Diagnostics aims to enhance patient access to timely and accurate testing for these infections, ultimately contributing to the fight against antimicrobial resistance.

Cavis Technologies is a start-up focused on developing healthcare devices aimed at diagnosing cardiovascular diseases. The company provides a unique device designed for invasive cardiology care units, enhancing control and safety during medical procedures. Its innovative device features a simple and robust design, utilizing a strategically positioned pressure sensor that minimizes hydrostatic error. This technology allows for effective assessment of the severity of narrowings in coronary arteries and myocardial disease, ultimately benefiting patients, cardiologists, and healthcare providers by improving diagnostic accuracy and patient outcomes.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, founded in 2017. The company is focused on developing a metabolism-based liquid biopsy platform that aids in the early detection and monitoring of cancer. This platform employs a novel in vitro diagnostic laboratory assay kit and artificial intelligence algorithms, which analyze biomarkers in blood and urine to identify cancer signatures. Elypta's technology offers comprehensive profiling of glycosaminoglycan metabolites and includes scoring software to support a wide range of cancer applications, from screening to treatment response monitoring. The company is currently conducting clinical trials, particularly the AURORAX series, to investigate its platform's efficacy in renal cell carcinoma and other cancer indications, aiming to reduce cancer mortality through timely intervention.

Predicare AB is a Swedish company that specializes in designing and developing decision support system solutions for the healthcare sector. Headquartered in Gothenburg, it offers the RETTS system, a fast emergency triage and treatment tool that helps healthcare professionals assess vital parameters during initial examinations. RETTS facilitates the collection of structured and standardized medical histories, allowing for effective matching of symptoms with vital signs. This clinical decision support tool enhances the decision-making process for medical practitioners, including those treating adults, children, pregnant women, and psychiatric emergency patients. Founded in 2010, Predicare aims to improve the quality and speed of care in emergency situations.

Empe Diagnostics specializes in developing rapid diagnostic solutions for infectious diseases, particularly targeting drug-resistant Tuberculosis (TB) and Sexually Transmitted Diseases (STDs). The company focuses on creating simple and efficient diagnostic kits that facilitate combinatorial and confirmatory point-of-care testing. By prioritizing early-stage diagnostics, Empe Diagnostics aims to enhance patient access to timely and accurate testing for these infections, ultimately contributing to the fight against antimicrobial resistance.

Single Technologies AB is a Stockholm-based company founded in 2012 that specializes in the development of advanced 3D sequencing technologies for genomics and diagnostics. The company focuses on creating innovative single-molecule-sensitive imaging systems that facilitate high-throughput and cost-effective DNA reading. By integrating techniques such as single-molecule detection, large-area confocal scanning, and nanotechnology, Single Technologies enables researchers and healthcare professionals to generate detailed genomic data. This capability supports accurate diagnoses and personalized treatment options in the healthcare industry, making significant contributions to research and drug discovery.

Athera Biotechnologies AB is a biopharmaceutical company based in Stockholm, Sweden, specializing in the development of targeted anti-inflammatory therapeutics and companion diagnostics for cardiovascular diseases (CVD). Founded in 2002, the company focuses on addressing unmet medical needs in the prevention and treatment of CVD through innovative approaches. Its product portfolio includes CVDefine, an immunological marker and ELISA kit designed for cardiovascular risk assessment, as well as several biopharmaceutical candidates. Among these is PC-mAb, a monoclonal antibody therapy aimed at preventing the uptake of oxidized low-density lipoprotein in macrophages, and Annexin A5, which seeks to prevent plaque rupture and atherothrombotic events. Athera's research is rooted in advancements made at the Karolinska Institutet and reflects a commitment to harnessing scientific breakthroughs for improved patient outcomes in the realm of cardiovascular health.

Likvor AB is a medical device company based in Umeå, Sweden, founded in 2007. The company specializes in developing systems for neurological investigations, particularly focusing on cerebrospinal fluid (CSF) dynamics. Its flagship product, the CELDA System, is designed to measure CSF pressure and flow, aiding in the diagnosis and treatment of conditions such as Normal Pressure Hydrocephalus (NPH). The CELDA System, which includes instruments, software, and a specialized bed, has been available since 2009 and is certified for use in multiple languages. Likvor AB collaborates with researchers from Umeå University and Umeå University Hospital to innovate and enhance methods for assessing CSF dynamics, ensuring that its products meet high standards of quality and effectiveness. The company is certified according to ISO-13485, highlighting its commitment to quality management in the medical device sector.

Lipigon Pharmaceuticals AB is a Swedish biopharmaceutical company founded in 2010, specializing in the development of therapeutics for dyslipidemia and metabolic diseases. The company focuses on innovative treatments targeting lipoprotein lipase (LPL), an enzyme linked to fat metabolism, which plays a significant role in conditions such as insulin resistance and metabolic syndrome. Lipigon is particularly dedicated to addressing rare diseases, including lipodystrophy and homozygous familial hypercholesterolemia, where existing treatment options are limited. The company's expertise in fat metabolism has led to a collaborative agreement with AstraZeneca to develop LPL-based pharmaceuticals, potentially yielding up to $110 million in milestone payments based on development and sales achievements. Lipigon Pharmaceuticals is headquartered in Umeå, Sweden.

Cartana AB is a biotechnology company based in Solna, Sweden, established in 2017. The company specializes in mapping gene expression in brain tissue using In Situ Sequencing (ISS), a cutting-edge technology that allows for the simultaneous analysis of hundreds of genes within individual cells while preserving tissue morphology. Cartana's primary product, the NeuroKit: Brain Cell Mapping, can identify over 100 genes in a single tissue section, providing high sensitivity and throughput for various research applications. The company also offers sequencing services that include sample preparation in their laboratory. By enabling detailed analysis of brain cells and other tissues, Cartana supports advancements in research, biomarker discovery, treatment validation, and potential diagnostic tools. As of August 2020, Cartana operates as a subsidiary of 10x Genomics, Inc.

Empe Diagnostics specializes in developing rapid diagnostic solutions for infectious diseases, particularly targeting drug-resistant Tuberculosis (TB) and Sexually Transmitted Diseases (STDs). The company focuses on creating simple and efficient diagnostic kits that facilitate combinatorial and confirmatory point-of-care testing. By prioritizing early-stage diagnostics, Empe Diagnostics aims to enhance patient access to timely and accurate testing for these infections, ultimately contributing to the fight against antimicrobial resistance.

PictureMyLife is an innovative platform designed to enhance communication for children with impaired comprehension skills, as well as their families and educators. Founded by Yvonne Malmström Grimme, Lollo Andström, Lisa Lidgren, and Maria Skantz, the company aims to replace traditional, cumbersome methods of communication, such as handwritten contact books and printed schedules, with a more efficient digital solution. The platform allows users to upload images and videos, providing a secure way to share personal stories and experiences. With a strong emphasis on protecting user data, PictureMyLife offers a web-based communication tool that is both accessible and inspiring, ultimately making life easier for children facing communication challenges. The founders bring extensive experience in communication and education, particularly within healthcare and social care sectors, to support their mission.

Medpro Clinic Group is a healthcare provider based in Sweden, operating six innovative care centers in the Västra Götaland region. The company offers a diverse range of medical services, including primary care, rehabilitation, vaccinations, dermatology, cardiology, and drug rehabilitation. Medpro Clinic Group is dedicated to delivering high-quality care with a personal touch, facilitated by a passionate and committed staff. By focusing on accessibility and continuity of care, the organization aims to meet the diverse healthcare needs of its patients effectively.

Liv Diagnostics, founded in 2016 and headquartered in Mölndal, Sweden, develops innovative diagnostic tools for cancer analysis. The company's primary product, CellRACE, measures the migration capacity of tumor cells to provide predictive information about the risk of metastasis. Unlike indirect diagnostic methods, Liv Diagnostics' technology directly analyzes cancer cell behavior by mimicking their natural environment in the human body. This approach allows physicians to observe how cells behave and treat them more efficiently.

Raytelligence AB is a Swedish company focused on developing advanced microwave sensors for the healthcare and industrial markets. Founded in 2015 as a subsidiary of Swedish Adrenaline, Raytelligence specializes in solutions that monitor vital signs such as heartbeat, movement, and body position. The company's flagship product, the RayVS1 sensor, is designed for home use and features capabilities for signal processing and analysis through a cloud service. In addition to its healthcare applications, Raytelligence has expanded into the industrial sector, securing clients in road construction and partnering with a major Swedish IT provider in the e-Health market. The team's expertise spans industrial design and radar signal processing, positioning Raytelligence as a key player in the development of innovative sensor technology.

1928 Diagnostics is a digital health company that specializes in bioinformatics, focusing on the analysis of DNA data to combat antibiotic resistance. The company provides a cloud-based platform designed to assist microbiologists in utilizing sequencing data for outbreak tracing and diagnostics. This user-friendly and secure service enables healthcare providers to effectively track, identify, and manage bacteria, viruses, and fungi, thereby enhancing infection control within hospitals. Additionally, 1928 Diagnostics serves customers across the healthcare, food, and environmental sectors, facilitating the global effort to minimize the spread of infectious agents.

MedFilm is a company focused on enhancing patient understanding of surgical interventions through the use of animated films. It specializes in creating three-dimensional animated patient films available in over a dozen languages, aimed at simplifying the communication of operations and treatments. These films are utilized in hospitals throughout Scandinavia, providing essential information to patients both upon admission and during recovery. Additionally, MedFilm's content is displayed on waiting room screens and made accessible online, ensuring that patients can easily access information about their procedures. By improving comprehension and encouraging patient participation, MedFilm supports healthcare providers in delivering better care.

PictureMyLife is an innovative platform designed to enhance communication for children with impaired comprehension skills, as well as their families and educators. Founded by Yvonne Malmström Grimme, Lollo Andström, Lisa Lidgren, and Maria Skantz, the company aims to replace traditional, cumbersome methods of communication, such as handwritten contact books and printed schedules, with a more efficient digital solution. The platform allows users to upload images and videos, providing a secure way to share personal stories and experiences. With a strong emphasis on protecting user data, PictureMyLife offers a web-based communication tool that is both accessible and inspiring, ultimately making life easier for children facing communication challenges. The founders bring extensive experience in communication and education, particularly within healthcare and social care sectors, to support their mission.

Inhalation Sciences Sweden AB is a company focused on developing and commercializing advanced laboratory instruments for inhalation research. Its flagship product, PreciseInhale, is a patented aerosol generation platform that enables the delivery of respirable dry powder aerosols, facilitating drug development from preclinical studies to human clinical trials. This innovative system allows for the testing of small amounts of drug substances, requiring only milligrams for comprehensive pharmacokinetic studies while providing high-resolution lung data with minimal variability. Additionally, the company offers the LaminarPace tool, designed for drying small quantities of drug substances. Inhalation Sciences provides contract research services to novel and generic inhalation drug developers, as well as toxicology and environmental research institutes, positioning itself as a leader in the inhalation and aerosolization field.

Learning to Sleep AB is a digital care provider headquartered in Malmo, Sweden, specializing in evidence-based programs aimed at improving sleep quality for individuals experiencing sleep disorders. Founded in 2010, the company offers two primary solutions: "Improve my Sleep," designed for those with minor sleep issues requiring small adjustments, and "Learning to Sleep," targeted at individuals with more severe problems to help restore their natural sleep patterns. These programs are accessible via web and mobile platforms, allowing users to engage with clinically proven methods for better sleep. Learning to Sleep has successfully assisted over 40,000 individuals in enhancing their sleep and overall quality of life, fostering strong relationships between patients and their psychologists through its innovative business model.

Attana AB is a biotechnology company headquartered in Stockholm, Sweden, that specializes in providing biologically relevant information to enhance the efficiency of pharmaceutical drug development. Founded in 2002, the company develops advanced analytical biosensor instruments capable of automated analysis of molecular interactions with cells and tissues. Attana's third-generation biosensors are designed to assess binding characteristics such as specificity, kinetics, and affinity of various biomolecules, including cells, antibodies, proteins, viruses, and bacteria. The company's technology has been validated by academic institutions, biotech firms, and pharmaceutical companies globally. In addition to its biosensor products, Attana offers contract research services, catering to clients in Europe and Asia, including academic institutions and the pharmaceutical and biotechnology sectors.